CB701

CB701 is a complement-targeting therapeutic candidate under development by Cascade Biotechnology for the treatment of prodromal schizophrenia. The drug leverages Cascade's proprietary sC3 complement-depleting platform, which utilizes protein engineering to modulate the complement system. Dysregulation of the complement pathway, particularly involving synaptic pruning and neuroinflammation, has been linked to the development of schizophrenia and first-episode psychosis. CB701 is designed to address these early pathological changes by depleting specific complement components. It is currently in the early discovery phase, undergoing in vitro research to validate its potential in addressing the role of complement dysregulation in early-stage psychiatric disease.